Abiraterone

Traitement médical du
Cancer de la Prostate:
du désert à la profusion
Prof. Karim Fizazi, MD, PhD
Institut Gustave Roussy
Villejuif, France

Disclosure
• Participation in advisory boards or as a
speaker for:
Amgen, Astellas-Medivation, Astrazeneca,
Bayer, BMS, Celgene, Dendreon, Exelixis,
Ipsen, Janssen-Cougar, Keocyt, Millennium-
Takeda, Novartis, Sanofi-Aventis

Advanced prostate cancer:
Natural history (in the 2000s)
Local Treatment
PSA relapse (ADT)
Metastatic Castrate-Resistant Prostate Cancer
Castrate-resistant, M0
Metastatic Hormone-Sensitive
prostate cancer
Docetaxel
Zoledronate
ADT

A decade of research
in prostate cancer
2004-2009:
No significant result
2010-2012:
- Sipuleucel-T
-Cabazitaxel
-Denosumab
-Abiraterone
-Alpharadin
-MDV 3100

Endocrine therapies
Testosterone
DNA
Cell division
Testis
Adrenals
Autocrine
secretion
Castration
(aLHRH
or surgery)
Abiraterone
Abiraterone
Androgen Receptor
inhibitors:
-Bicalutamide
-Enzalutamide
(MDV 3100)